Results 41 to 50 of about 258,914 (247)

Elevated serum polyclonal immunoglobulin free light chains in patients with severe asthma

open access: yesFrontiers in Pharmacology, 2023
Background: Inflammation plays a pivotal role in the pathophysiology of asthma. Free light chains (FLC) can cause inflammation by mast cell antigen-activation. Serum immunoglobulin (Ig) FLC κ, but not λ, were shown elevated in adult males with asthma. We
Umberto Basile   +12 more
doaj   +1 more source

Structural insights and biomedical potential of IgNAR scaffolds from sharks [PDF]

open access: yes, 2014
Peer reviewedPublisher ...
Barelle, Caroline   +5 more
core   +1 more source

A Hands-on Activity for V(D)J Recombination in an Undergraduate Immunology Class

open access: yesJournal of Microbiology & Biology Education, 2023
This learning activity teaches the difficult concept of V(D)J recombination as it occurs in B cells. Following the traditional lecture, this hands-on activity uses pipe cleaners of various colors representing variable, joining, and diversity gene ...
Kelly N. Hallstrom, Gwendowlyn S. Knapp
doaj   +1 more source

Serum Free Light Chains Removal by HFR Hemodiafiltration in Patients with Multiple Myeloma and Acute Kidney Injury. a Case Series [PDF]

open access: yes, 2018
Background/Aims: Multiple myeloma (MM) represents 10% of all haematologic malignancies. Renal involvement occurs in 50% of MM patients; of them, 12-20% have acute kidney injury (AKI), with 10% needing dialysis at presentation. While hemodialysis (HD) has
Antolino, Giusy   +7 more
core   +2 more sources

Significant differences in physicochemical properties of human immunoglobulin kappa and lambda CDR3 regions

open access: yesFrontiers in Immunology, 2016
Antibody variable regions are composed of a heavy and a light chain and in humans there are two light chain isotypes: kappa and lambda. Despite their importance in receptor editing, the light chain is often overlooked in the antibody literature, with the
Catherine L Townsend   +7 more
doaj   +1 more source

Human Gm, Km, and Am Allotypes: WHO/IMGT Nomenclature and IMGT Unique Numbering for Immunoinformatics and Therapeutical Antibodies

open access: yesBioMedInformatics, 2023
Human immunoglobulin allotypes are allelic antigenic determinants (or “markers”) determined serologically, classically by hemagglutination inhibition, on the human immunoglobulin (IG) or antibody heavy and light chains. The allotypes have been identified
Marie-Paule Lefranc, Gérard Lefranc
doaj   +1 more source

Comparative Aspects of Immunoglobulin Gene Rearrangement Arrays in Different Species

open access: yesFrontiers in Immunology, 2022
Studies in humans and mice indicate the critical role of the surrogate light chain in the selection of the productive immunoglobulin repertoire during B cell development.
Marek Sinkora   +5 more
doaj   +1 more source

Recommendations for use of free light chain assay in monoclonal gammopathies [PDF]

open access: yesJournal of Medical Biochemistry, 2010
The serum immunoglobulin free light chain assay measures levels of free k and l immunoglobulin light chains. There are three major indications for the free light chain assay in the evaluation and management of multiple myeloma and related plasma cell ...
Radović Vesna V.
doaj  

Regulated progression of B lymphocyte differentiation from cultured fetal liver. [PDF]

open access: yes, 1987
Lymphoid fetal liver cultures (LFLC) are long-term, nontransformed cultures of early B lymphoid lineage cells which appear developmentally blocked at the pre-B stage in vitro.
Denis, KA, Dorshkind, K, Witte, ON
core   +2 more sources

Evaluating the heavy/light chain immunoglobulin biomarker for early relapse detection in multiple myeloma: A comparative study with conventional methods

open access: yesClinical Immunology Communications
Objectives: The objective of this study is to evaluate the use of the immunoglobulin heavy/light chain biomarker in the early detection of biochemical relapse in patients with multiple myeloma under treatment.
Carla Azevedo   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy